Bulent Ozpolat

Assoc. Prof.Dr.

Houston Methodist

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Bulent Ozpolat is an Associate Professor at Houston Methodist in the United States. His research interests include cancer biology, model systems in cancer therapy, and molecular mechanisms involving RNAi and miRNA therapeutics. His recent publications focus on topics such as stem cell niche maintenance in ductal carcinoma, the role of eukaryotic elongation factor-2 kinase in cancer, and the therapeutic potential of nanoparticle-mediated drug delivery.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Bulent Ozpolat

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Mostafa Borahay

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES

View details

HAMADA MOKHLIS

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Caroline Chung

Vice President & Chief Data Officer

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Joseph Butner

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Martina Tesikova

Associate Professor

University of South-Eastern Norway

NORWAY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bulent Ozpolat

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study.

Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: homology modeling, molecular docking, and molecular dynamics simulation.

Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer.

Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study.

RNAi-based therapeutics and tumor targeted delivery in cancer.

miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K.

CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy.

Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.

Stress-Mediated Reprogramming of Prostate Cancer One-Carbon Cycle Drives Disease Progression.

Collaborators (6)

Bulent Ozpolat

Mostafa Borahay

HAMADA MOKHLIS

Caroline Chung

Joseph Butner

Martina Tesikova

Make your next move.